Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Van Dalen, Elvira C ^a   Van Der Pal, Helena J H ^b   Caron, Huib N ^a   Kremer, Leontien C M ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adult; Anthracyclines *administration dosage; adverse effects ; Antibiotics; Antineoplastic *administration dosage; adverse effects ; Cardiac output; Child; Heart diseases chemically induced ; Heart *drug effects ; Humans; Low chemically induced; prevention control ; Neoplasms *drug therapy ; Randomized controlled trials as topic

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN;

CANCER PATIENT; CARDIOTOXICITY; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG INFUSION; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; EMBASE; HEART FAILURE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SOLID TUMOR; SYSTEMATIC REVIEW;

EID: 77950185719     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005008.pub3     Document Type: Review

References (84)

1. Budman 1998 {published data only} Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al.Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute 1998;90:1205-11.
2. Casper 1991 {published data only} Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Friedrich C, et al.A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991;68:1221-9.
3. Escherich 2007 {published data only} Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klinische Pädiatrie 2007; 219:134-8.
4. Fountzilas 2008 {published data only} Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, et al.Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Annals of Oncology 2008;19:853-60.
5. Heidenreich 2004 {published and unpublished data} Heidenreich A, Sommer F, Ohlmann CH, Schrader AJ, Olbert P, Goecke J, et al.Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormonerefractory prostate carcinoma. Cancer 2004;101:948-56.
6. Hortobagyi 1989 {published data only} Hortobagyi GN, Yap H, Kau SW, Fraschini G, Ewer MS, Chawla SP, et al.A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. American Journal of Clinical Oncology 1989;12:57-62.
7. Linden 2007 {published data only} Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW Jr, Shapiro CL, et al.Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). Journal of Clinical Oncology 2007;25:656-61.
8. Lipshultz 2002 {published data only} Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, et al.Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. Journal of Clinical Oncology 2002;20:1677-82.
9. Shapira 1990 {published data only} Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen: a prospective randomized evaluation. Cancer 1990;65:870- 3.
10. Steinherz 1993 {published data only} Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. Cancer 1993; 72:3120-30.
11. Zalupski 1991 {published data only} Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, et al.Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group Study. Journal of the National Cancer Institute 1991;83:926-32.
12. Adam 1994 {published data only} Adam Z, Elbl L, Vorlicek J, Hajek R, Tomiska M, Hejlova N, et al.Lower cardiotoxicity of adriamycin during continuous administration to patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone. Vnitrni Lekarstvi 1994;40:506-12.
13. Alba 2004 {published data only} Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, et al.Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as firstline treatment of metastatic breast cancer: a spanish breast cancer research group (GEICAM-9903) phase III study. Journal of Clinical Oncology 2004;22:2587-93.
14. Bastholt 1996 {published data only} Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, et al.Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology 1996;14:1146-55.
15. Berchem 1996 {published data only} Berchem GJ, Ries F, Hanfelt J, Duhem C, Keipes M, Delagardelle C, et al.Epirubicin cardiotoxicity: a study comparing low- with high-dose intensity weekly schedules. Support Care Cancer 1996;4: 308-12.
16. Berrak 2001 {published data only} Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA, et al.Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous infusion schedules. Oncology Reports 2001;8:611-14.
17. Blomqvist 1993 {published data only} Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Helle L. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. Journal of Clinical Oncology 1993;11:467-73.
18. Buzdar 2007 {published data only} Buzdar AU. Adjuvant chemotherapy for high-risk operable breast cancer. Journal of Clinical Oncology 2007;25:1642-4.
19. Carmo-Pereira 1987 {published data only} Carmo-Pereira J, Oliviera Costa F, Henriques E, Godinho F, Cantinho-Lopes MG, Sales-Luis A, et al.A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. British Journal of Cancer 1987;56:471-73.
20. Carrio 1993 {published data only} Carrio I, Lopez-Pousa A, Estorch M, Duncker D, Berna L, Torres G, et al.Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. Journal of Nuclear Medicine 1993;34:1503-7.
21. Creutzig 2007 {published data only} Creutzig U, Diekamp S, Zimmermann M, Reinhardt D. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatric Blood and Cancer 2007;48:651-62.
22. Dorup 2004 {published data only} Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function. Heart 2004;90:1214-6.
23. Ehrlich 1979 {published data only} Ehrlich CE, Einhorn L, Williams SD, Morgan J. Chemotherapy for stage III-IV epithelial ovarian cancer with cisdichlorodiammineplatinum (II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treatment Reports 1979;63:281-8.
24. Eksborg 1997 {published data only} Eksborg S, Bjorkholm M, Hast R, Fagerlund E. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite - a comparison of bolus versus 2 h infusion during a 3 day course. Anti-Cancer Drugs 1997;8:42-7.
25. Ewer 1998 {published data only} Ewer MS, Jaffe N, Ried H, Zietz HA, Benjamin RS. Doxorubicin cardiotoxicity in children: comparison of consecutive divided daily dose administration schedule with single dose (rapid) infusion administration. Medical and Pediatric Oncology 1998;31:512-5.
26. Gabizon 2008 {published data only} Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemotherapy and Pharmacology 2008;61:695-702.
27. Gupta 2003 {published data only} Gupta M, Steinherz PG, Cheung NK, Steinherz L. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Medical and Pediatric Oncology 2003;40:343-7.
28. Habeshaw 1991 {published data only} Habeshaw T, Paul J, Jones R, Stallard S, Kaye SB, Soukop M, et al.Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. Journal of Clinical Oncology 1991;9:295-304.
29. Henderson 2003 {published data only} Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al.Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology 2003;21:976-83.
30. Hochster 1985 {published data only} Hochster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM. 4'epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. Journal of Clinical Oncology 1985;3:1535-40.
31. Hoeltgen 1983 {published data only} Hoeltgen TM, MacIntyre JM, Perlia CP, Lagakos SW, Stolbach LL, Bennett JM. Adriamycin and cytoxan in the treatment of inoperable lung cancer. Cancer 1983;51:2005-12.
32. Hubert 2000 {published data only} Hubert A, Lyass O, Pode D, Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormonerefractory prostate cancer. Anti-Cancer Drugs 2000;11:123-7.
33. Hunault-Berger 2001 {published data only} Hunault-Berger M, Milpied N, Bernard M, Jouet JP, Delain M, Desablens B, et al.Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study. Leukemia 2001;15: 898-902.
34. Irwin 1980 {published data only} Irwin LE, Chlebowski RT, Weiner JM, Reynolds R, Pugh RP, Ryden VMJ, et al.Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a western cancer study group trial. Cancer Treatment Reports 1980;64:981-4.
35. ISRCTN 83324925 {published and unpublished data} A randomized comparative trial of infusional ECF versus conventional FEC as adjuvant chemotherapy in patients with poor prognosis breast cancer. ISRCTN Register (ongoing studies).
36. Kilickap 2007 {published data only} Kilickap S, Barista I, Akgul E, Aytemir K, Aksoy S, Tekuzman AG. Early and late arrhythmogenic effects of doxorubicin. Southern Medical Journal 2007;100:262-5.
37. Kinoshita 2004 {published data only} Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, et al.A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002. International Journal of Hematology 2004;80:341-50.
38. Krupicka 2002 {published data only} Krupicka J, Markova J, Pohlreich D, Kozak T, Linkova H, Diehl V. Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the german Hodgkin's lymphoma study group. Leukemia & Lymphoma 2002;43:2325-9.
39. Lalisang 1997 {published data only} Lalisang RI, Wils JA, Nortier HW, Burghouts JTh, Hupperets PS, Erdkamp FL, et al.Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer. Journal of Clinical Oncology 1997;15: 1367-76.
40. Levitt 2004 {published data only} Levitt GA, Dorup I, Sorensen K, Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity?. British Journal of Haematology 2004;124:463-8.
41. Lippens 1987 {published data only} Lippens RJJ, Van Lier HJJ, Zwagemakers JFC. Tolerance of 24-hour infusions of low-and high-dose bolus injections of adriamycin in children. Pediatric Hematology and Oncology 1987;4:189-97.
42. Luck (study A) 1997 {published data only} Luck HJ, Du Bois A, Thomssen C, LIsboa B, Untch M, Kohler G, et al.A Phase II study. Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer. Oncology 1997;11:34-7.
43. Luck (study B) 1997 {published data only} Luck HJ, Thomssen C, Du Bois A, Untch M, Lisboa M, Kohler G, et al.Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Seminars in Oncology 1997;24:S17-35-S17-39.
44. Marschner 1994 {published data only} Marschner N, Kreienberg R, Souchon R, Rath U, Eggeling B, Voigtmann R, et al.Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial. Seminars in Oncology 1994;21:10-6.
45. Miller 1999 {published data only (unpublished sought but not used)} Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, et al.Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. Journal of Clinical Oncology 1999;17:3033-7.
46. Nemoto 1987 {published data only} Nemoto T, Rosner D, Diaz R, Dao T, Sponzo R, Cunningham T, et al.Combination chemotherapy for metastatic breast cancer, comparison of multiple drug therapy with 5-flourouracil, cytoxan and prednisone with adriamycin or adrenalectomy. Cancer 1978; 41:2073-7.
47. Nielsen 1998 {published and unpublished data} Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, et al.High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. British Journal of Cancer 1998;78:1634-9.
48. O'Bryan 1977 {published data only} O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, et al.Dose response evaluation of adriamycin in human neoplasia. Cancer 1977;39:1940-8.
49. Rubin 1980 {published data only} Rubin J, Decker DA, Ahmann DL, Eagan RT, Ingle JN, Hahn R. An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer. Oncology 1980;37:149-51.
50. Stapleton 2007 {published data only} Stapleton GE, Stapleton SL, Martinez A, Ayres NA, Kovalchin JP, Bezold LI, et al.Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines. Journal of the American Society of Echocardiography 2007;20:492-7.
51. Sutton 1989 {published data only} Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. Journal of Clinical Oncology 1989;7: 223-9.
52. Swain 2003 {published data only} Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin, a retrospective analysis of three trials. Cancer 2003;97:2869-79.
53. SWOG S0221 {published data only} SWOG S0221 - Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer. http://www.kccop.org/breast/swog0221.htm.
54. Torti 1983 {published data only} Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, et al.Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule, assessment by endomyocardial biopsy. Annals of Internal Medicine 1983;99:745-9.
55. Umsawasdi 1989 {published data only} Umsawasdi T, Valdivieso M, Booser DJ, Barkley HT, Ewer M, MacKay B, et al.Weekly doxorubicin every 3 weeks in cyclophosphamide, doxorubicin and cisplatin chemotherapy for non-small cell lung cancer. Cancer 1989;64:1995-2000.
56. Valdivieso 1984 {published data only} Valdivieso M, Burgess MA, Ewer MS, Mackay B, Wallace S, Benjamin RS, et al.Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. Journal of Clinical Oncology 1984;2: 207-14.
57. Wood 1994 {published data only} Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al.Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. New England Journal of Medicine 1994;330:1253-1259.
58. Woodward 2003 {published data only} Woodward WA, Strom EA, McNeese MD, Perkins GH, Outlaw EL, Hortobagyi GN, et al.Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. International Journal of Radiation Oncology, Biology, Physics 2003;57:3270335.
59. Yates 1982 {published data only} Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al.Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60:454-62.
60. Ruiz 2006 {published data only} Ruiz M, Bayo J, Moreno Nogueira JA, Dorta J, Casas A, Morales M. Randomized open label phase II study of pegylated liposomal doxorubicine (PLD) four or six-week scheduled in metastatic breast cancer (MBC) patients (p). ASCO Annual Meeting. 2006.
61. Batist 2001 Batist G, Ramakriskan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al.Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic breast cancer. Journal of Clinical Oncology 2001;19:1444-54.
62. Billingham 1978 Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Reports 1978;62:865-72.
63. Bonadonna 1969 Bonadonna G, Monfardini S. Cardiac toxicity of daunorubicin. Lancet 1969;1:837.
64. Fountzilas 2005 Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, et al.Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology 2005;16:1762-71.
65. Higgins 2005 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews on Interventions Version 4.2.5 [updated May 2005]. John Wiley & Sons Ltd, Chichester (UK).
66. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
67. Kremer 2001 Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voûte PA. Anthracycline induced clinical heart failure in a cohort of 607 children: a long-term follow-up study. Journal of Clinical Oncology 2001;19:191-6.
68. Kremer 2002a Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology 2002;13:819-29.
69. Kremer 2002b Kremer LC, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Annals of Oncology 2002;13:503-12.
70. Lefrak 1973 Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14.
71. Legha 1982 Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, et al.Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Annals of Internal Medicine 1982; 96:133-9.
72. Meinardi 2002 Meinardi MT, Van der Graaf WTA, Gietema JA, Van den Berg MP, Sleijfer DT, De Vries EGE, et al.Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart 2002;88:81-2.
73. Millikan 2003 Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, et al.Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. Journal of Clinical Oncology 2003;21:878-83.
74. Muggia 1991 Muggia FM, Green MD. New anthracycline antitumor antibiotics. Critical Reviews in Oncology/Hematology 1991;11:43- 64.
75. Ng 2006 Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Seminars in Oncology 2006;33:2-14.
76. Nousiainen 2002 Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. British Journal of Cancer 2002;86:1697-1700.
77. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
78. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273: 408-12.
79. Shan 1996 Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Annals of Internal Medicine 1996;125:47-58.
80. Silverman 2001 Silverman LB, Gelber RD, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, et al.Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-18.
81. Simbre 2005 Simbre II VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy, implications for children. Pediatric Drugs 2005;7:187-202.
82. Verbel 2002 Verbel DA, Heller G, Kelly WK, Scher HI. Quantifying the amount of variation in survival explained by prostate-specific antigen. Clinical Cancer Research 2002;8:2576-9.
83. Wexler 1996 Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, et al.Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. Journal of Clinical Oncology 1996;14:362-372.
84. Van Dalen 2006 Van Dalen EC, Van der Pal HJH, Caron HN, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2006, Issue 4.[Art. No.: CD005008. DOI: 10.1002/14651858.CD005008. pub3]